Paromomycin is an inexpensive (US$10) and effective treatment for<unk> . The treatment is determined by where the disease is acquired, the species of Leishmania, and the type of infection. For visceral<unk>  in India, South America, and the Mediterranean, liposomal amphotericin B is the recommended treatment and is often used as a single dose. Rates of cure with a single dose of amphotericin have been reported as 95%. In India, almost all infections are resistant to pentavalent antimonials. In Africa, a combination of pentavalent antimonials and paromomycin is recommended. These, however, can have significant side effects. Miltefosine, an oral medication, is effective against both visceral and cutaneous<unk> . Side effects are generally mild, though it can cause birth defects if taken within 3 months of getting pregnant. It does not appear to work for L. major or L. braziliensis. The evidence around the treatment of cutaneous<unk>  is poor. A number of topical treatments may be used for cutaneous<unk> . Which treatments are effective depends on the strain, with topical paromomycin effective for L. major, L. tropica, L. mexicana, L. panamensis, and L. braziliensis. Pentamidine is effective for L. guyanensis. Oral fluconazole or itraconazole appears effective in L. major and L. tropica. There is limited evidence to support the use of heat therapy in cutaneous<unk>  as of 2015. There are no studies determining the effect of oral nutritional supplements on visceral<unk>  being treated with anti-leishmanial drug therapy.
Leishmaniasis
Sporotrichosis
Isosporiasis
Tungiasis
Psittacosis
Trypanosomiasis
Mansonelliasis
Scarabiasis